Top

Molecular Imaging and Biology

Published in:

01-04-2019

[⁶⁸Ga]RGD Versus [¹⁸F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide

Authors: Claire Provost, Laura Rozenblum-Beddok, Valérie Nataf, Fatiha Merabtene, Aurélie Prignon, Jean-Noël Talbot

Published in: Molecular Imaging and Biology | Issue 2/2019

Abstract

Purpose

The aim of this study was to evaluate positron emission tomography (PET) imaging with [⁶⁸Ga]NODAGA-c(RGDfK) ([⁶⁸Ga]RGD), in comparison with 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG), for early monitoring of the efficacy of an antiangiogenic agent associated or not with chemotherapy, in a mouse model of glioblastoma (GB).

Procedures

Mice bearing U87MG human GB cells line were parted into five groups of five mice each. One group was imaged at baseline before the treatment phase; another group was treated with bevacizumab (BVZ), another group with temozolomide (TMZ), another group with both agents, and the last one was the control group. Tumors growth and biological properties were evaluated by caliper measurements and PET imaging at three time points (baseline, during treatment t1 = 4–6 days and t2 = 10–12 days). At the end of the study, tumors were counted and analyzed by immunohistochemistry (CD31 to evaluate microvessel density).

Results

The tumor volume assessed by caliper measurements was significantly greater at t1 in the control group than in the TMZ + BVZ-treated group or in the BVZ-treated group. At t2, tumor volume of all treated groups was significantly smaller than that of the control group. [¹⁸F]FDG PET failed to reflect this efficacy of treatment. In contrast, at t1, the [⁶⁸Ga]RGD tumor uptake was concordant with tumor growth in controls and in treated groups. At t2, a significant increase in tumor uptake of [⁶⁸Ga]RGD vs. t1 was only observed in the TMZ-treated group, reflecting a lack of angiogenesis inhibition, whereas TMZ + BVZ resulted in a dramatic tumor arrest, reduction in microvessel density and stable tumor [⁶⁸Ga]RGD uptake.

Conclusions

[⁶⁸Ga]RGD is a useful PET agent for in vivo angiogenesis imaging and can be useful for monitoring antiangiogenic treatment associated or not with chemotherapy.

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRefPubMed

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186CrossRefPubMed

Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–286CrossRefPubMed

Folkman J (2007) Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 42:1–11CrossRefPubMed

Ivy SP, Wick JY, Kaufman BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569–579CrossRefPubMed

Tarallo V, De Falco S (2015) The vascular endothelial growth factors and receptors family: up to now the only target for anti-angiogenesis therapy. Int J Biochem Cell Biol 64:185–189CrossRefPubMed

Bellou S, Pentheroudakis G, Murphy C, Fotsis T (2013) Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett 338:219–228CrossRefPubMed

Sennino B, McDonald DM (2012) Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12:699–709CrossRefPubMedPubMedCentral

Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY (2010) Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncology 12:603–607CrossRefPubMedPubMedCentral

10.

Ye W (2016) The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev Cell 37:114–125CrossRefPubMed

11.

Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E (2012) FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro-Oncology 14:649–657CrossRefPubMedPubMedCentral

12.

Goggi JL, Bejot R, Moonshi SS, Bhakoo KK (2013) Stratification of ¹⁸F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med 54:1630–1636CrossRefPubMed

13.

Bao X, Wang MW, Luo JM, Wang SY, Zhang YP, Zhang YJ (2016) Optimization of early response monitoring and prediction of cancer antiangiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters. Theranostics 6:2084–2098CrossRefPubMedPubMedCentral

14.

Corroyer-Dulmont A, Peres EA, Gerault AN, Savina A, Bouquet F, Divoux D, Toutain J, Ibazizène M, MacKenzie ET, Barré L, Bernaudin M, Petit E, Valable S (2016) Multimodal imaging based on MRI and PET reveals [¹⁸F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. Eur J Nucl Med Mol Imaging 43:682–694

15.

Sheldrake HM, Patterson LH (2009) Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets 9:519–540CrossRefPubMed

16.

Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22CrossRefPubMedPubMedCentral

17.

Gaertner FC, Souvatzoglou M, Brix G, Beer AJ (2012) Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol 13:552–570CrossRefPubMed

18.

Niu G, Chen X (2016) RGD PET: from lesion detection to therapy response monitoring. J Nucl Med 57:501–502CrossRefPubMed

19.

Zhang H, Liu N, Gao S, Hu X, Zhao W, Tao R, Chen Z, Zheng J, Sun X, Xu L, Li W, Yu J, Yuan S (2016) Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT scan predict treatment sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J Nucl Med 57:524–529CrossRefPubMed

20.

Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS (2015) Glioblastoma multiforme recurrence: an exploratory study of ¹⁸F FPPRGD2 PET/CT. Radiology 277:497–506CrossRefPubMed

21.

Bozon-Petitprin A, Bacot S, Gauchez AS, Ahmadi M, Bourre JC, Marti-Batlle D, Perret P, Broisat A, Riou LM, Claron M, Boturyn D, Fagret D, Ghezzi C, Vuillez JP (2015) Targeted radionuclide therapy with RAFT-RGD radiolabelled with ⁹⁰Y or ¹⁷⁷Lu in a mouse model of αvβ3-expressing tumours. Eur J Nucl Med Mol Imaging 42:252–263CrossRefPubMed

22.

Guo N, Zhang F, Zhang X, Guo J, Lang L, Kiesewetter DO, Niu G, Li Q, Chen X (2015) Quantitative evaluation of tumor early response to a vascular-disrupting agent with dynamic PET. Mol Imaging Biol 17:865–873CrossRefPubMedPubMedCentral

23.

Cui Y, Liu H, Liang S, Zhang C, Cheng W, Hai W, Yin B, Wang D (2016) The feasibility of ¹⁸F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with ¹⁸F-FDG. Oncotarget 7:27243–27254PubMedPubMedCentral

24.

Kazmierczak PM, Todica A, Gildehaus FJ, Hirner-Eppeneder H, Brendel M, Eschbach RS, Hellmann M, Nikolaou K, Reiser MF, Wester HJ, Kropf S, Rominger A, Cyran CC (2016) ⁶⁸Ga-TRAP-(RGD)3 hybrid imaging for the in vivo monitoring of αvβ3-integrin expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer. PLoS One 11:e0168248CrossRefPubMedPubMedCentral

25.

Rylova SN, Barnucz E, Fani M, Braun F, Werner M, Lassmann S, Maecke HR, Weber WA (2014) Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? J Nucl Med 55:1878–1884CrossRefPubMed

26.

Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an ¹⁸F-labeled αvβ3-integrin and αvβ5-integrin imaging agent. J Nucl Med 52:424–430CrossRefPubMed

27.

Eo JS, Jeong JM (2016) Angiogenesis imaging using ⁶⁸Ga-RGD PET/CT: therapeutic implications. Semin Nucl Med 46:419–427CrossRefPubMed

28.

Haubner R, Maschauer S, Prante O (2014) PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed Res Int 2014:871609PubMedPubMedCentral

29.

Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, von Guggenberg E, Pichler BJ, Virgolini I, Decristoforo C, Haubner R (2011) [⁶⁸Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging 38:1303–1312CrossRefPubMed

30.

Haubner R, Finkenstedt A, Stegmayr A, Rangger C, Decristoforo C, Zoller H, Virgolini IJ (2016) [⁶⁸Ga]NODAGA-RGD—metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Eur J Nucl Med Mol Imaging 43:2005–2013CrossRefPubMedPubMedCentral

31.

Provost C, Prignon A, Rozenblum-Beddok L, Bruyer Q, Dumont S, Merabtene F, Nataf V, Bouteiller C, Talbot JN (2018) Comparison and evaluation of two RGD peptides labelled with ⁶⁸Ga or ¹⁸F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. Oncotarget 9:19307–19316CrossRefPubMedPubMedCentral

32.

Frosina G (2016) Non-routine tracers for PET imaging of high-grade glioma. Anticancer Res 36:3253–3260PubMed

33.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA (2013) Continuous daily sunitinib for recurrent glioblastoma. J Neuro-Oncol 111:41–48CrossRef

34.

Corroyer-Dulmont A, Peres EA, Petit E et al (2013) Detection of glioblastoma response to temozolomide combined with bevacizumab based on muMRI and muPET imaging reveals [¹⁸F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro-Oncology 15:41–56CrossRefPubMed

35.

Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT (2014) Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 20:5023–5031CrossRefPubMedPubMedCentral

36.

Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ (2003) Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 100:7785–7790CrossRefPubMedPubMedCentral

37.

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35–52CrossRefPubMedPubMedCentral

38.

Beal K, Abrey LE, Gutin PH (2011) Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 6:2CrossRefPubMedPubMedCentral

39.

Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A, Siemianowicz K, Likus W, Wiechec E, Toyota BD, Hoshyar R, Seyfoori A, Sepehri Z, Ande SR, Khadem F, Akbari M, Gorman AM, Samali A, Klonisch T, Ghavami S (2018) Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther 184:13-41

40.

Xue W, Du X, Wu H, Liu H, Xie T, Tong H, Chen X, Guo Y, Zhang W (2017) Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment. Sci Rep 7:13894CrossRefPubMedPubMedCentral

Title: [68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide
Authors: Claire Provost
Laura Rozenblum-Beddok
Valérie Nataf
Fatiha Merabtene
Aurélie Prignon
Jean-Noël Talbot
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Molecular Imaging and Biology / Issue 2/2019
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-1224-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

[⁶⁸Ga]RGD Versus [¹⁸F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

How Long of a Dynamic 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) PET Acquisition Is Needed for Robust Kinetic Analysis in Breast Cancer?

Imaging Pulmonary Foreign Body Reaction Using [125I]iodo-DPA-713 SPECT/CT in Mice

SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [18F]FE@SNAP and [11C]SNAP-7941

Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer

Detection of Sentinel Lymph Nodes with Near-Infrared Imaging in Malignancies

Evaluation of Glucose Uptake and Uncoupling Protein 1 Activity in Adipose Tissue of Diabetic Mice upon β-Adrenergic Stimulation